UCLA spinout's microbiome-based weight loss therapy Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 25 February, 2026

Rethink what's possible for mature products — Download the playbook sponsored by Cencora

presented by Health Eco­nom­ic Out­comes of the On­co­type DX Breast Re­cur­rence Test at a Pop­u­la­tion Health Lev­el

spotlight Who’s leading LGBTQ+ inclusion in biopharma? Nominate them for Endpoints’ annual report

news GSK to buy pulmonary hypertension biotech for $950M Polymer nanoparticle startup raises $60M for mRNA diabetes therapy UCLA spinout raises $11M to test microbiome-based weight loss therapy

Innovation in biopharmaceuticals: A conversation with Fujifilm leaders sponsored by Fujifilm From structure to selectivity: Federated AI for collaborative binding affinity prediction sponsored by Rhino Federated Computing

After years of rough sledding, biotech investors are getting back to work. Join us for a data-driven look at the field’s top VCs and their strategies for 2026. Get your spot now.

endpoints pharma HHS commits up to $144M to study anti-aging approaches via ARPA-H Novo Nordisk to slash Wegovy list price in half in 2027  Industry groups lay out potential legal strategy against CMS pricing demos Immedica wins accelerated approval for rare disease drug, plans to sell PRV Hims says it spoke with stakeholders to pull weight loss pill

in case you missed it 1. Failing to find a buyer, BioMarin pulls Roctavian in gene therapy's biggest disappointment 2. Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market 3. Patient dies in MacroGenics' cancer study, FDA puts trial on hold 4. Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push 5. Astellas pays $240M cash for Vir's prostate cancer drug 6. Abcuro plans to proceed with drug that failed pivotal muscle weakness trial 7. News Briefing Beam Therapeutics' new PKU program; Protara's bladder cancer data